New study aims to tame high potassium in kidney patients with standardized care

NCT ID NCT06884267

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a standardized care plan can help chronic kidney disease patients better control high potassium levels while optimizing their RAASi medications. About 1,000 participants will receive the care plan, which includes doctor training and patient education. The main goal is to see if more patients achieve normal potassium levels and optimal medication use after 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: standardized hyperkalemia management implementation (clinical pathway and education)
What this could lead to: If successful, this could establish a practical, guideline-based care approach to help kidney disease patients better manage high potassium levels while optimizing their heart-kidney protective medications.
What could go wrong: This is an early-stage, single-arm study without a comparison group, so results may not prove the approach is better than usual care. Success depends on real-world adherence and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease Hyperkalemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERKALEMIA

Contacts and locations

Locations

Research Site

Beijing, 100029, China
Research Site

Benxi, 117000, China
Research Site

Changchun, 130041, China
Research Site

Changsha, 410008, China
Research Site

Changsha, 410013, China
Research Site

Changsha, 410300, China
Research Site

Chengdu, 610031, China
Research Site

Chengdu, 610041, China
Research Site

Chengdu, 610078, China
Research Site

Chongqing, 400042, China
Research Site

Dalian, 116023, China
Research Site

Fuyang, 236600, China
Research Site

Fuzhou, 350005, China
Research Site

Fuzhou, 350031, China
Research Site

Gejiu, 661099, China
Research Site

Guangzhou, 510280, China
Research Site

Guangzhou, 510530, China
Research Site

Guiyang, 510630, China
Research Site

Haikou, 570311, China
Research Site

Hangzhou, 310006, China
Research Site

Hefei, 230001, China
Research Site

Hohhot, 10050, China
Research Site

Jinan, 250012, China
Research Site

Jinan, 250021, China
Research Site

Kunming, 650021, China
Research Site

Kunming, 650101, China
Research Site

Lanzhou, 730030, China
Research Site

Nanchang, 330006, China
Research Site

Nanning, 530021, China
Research Site

Nantong, 226001, China
Research Site

Ningbo, 315010, China
Research Site

Pingdingshan, 467000, China
Research Site

Qiqihar, 161000, China
Research Site

Shanghai, 200025, China
Research Site

Shanghai, 200032, China
Research Site

Shanghai, 200233, China
Research Site

Shenyang, 110001, China
Research Site

Shijiazhuang, 50051, China
Research Site

Taiyuan, 030001, China
Research Site

Tianjin, 300192, China
Research Site

Ürümqi, 830054, China
Research Site

Wuhan, 430022, China
Research Site

Wuhu, 241000, China
Research Site

Wuxi, 214062, China
Research Site

Xi'an, 710061, China
Research Site

Xining, 810001, China
Research Site

Xinxiang, 453100, China
Research Site

Yinchuan, 750004, China
Research Site

Zhengzhou, 450003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.